Pharmaceutical companies are avoiding steep price cuts proposed in Trump's latest Medicare plan.

Healthcare Economics PoliticsOct 1, 2026score 0.182 posts · 0 replies across 1 instances

The thread discusses a news article about pharmaceutical companies avoiding significant price cuts in Trump's latest Medicare plan. The posts highlight the implications for healthcare policy and business practices. This is relevant due to the potential impact on healthcare costs and industry regulations.

Claims

Parent: HealthcareEntity: Pharmaceutical CompaniesImpact: negativeDate: Oct 1, 2026Target: Pharmaceutical companies avoiding steep price cuts in Trump's Medicare plan

Source posts

@[email protected]

Pharma Escapes Steep Price Cuts in Trump’s Latest Medicare Plan
https://news.bloombergtax.com/daily-tax-report/pharma-escapes-steep-price-cuts-in-trumps-latest-medicare-plan?utm_source=flipboard&utm_medium=activitypub 

Posted into Tax Law @tax-law-BloombergLaw

1 boosts · 0 favs · 0 replies · Oct 1, 2026

@[email protected]

Pharma Escapes Steep Price Cuts in Trump’s Latest Medicare Plan
https://news.bloomberglaw.com/health-law-and-business/pharma-escapes-steep-price-cuts-in-trumps-latest-medicare-plan?utm_source=flipboard&utm_medium=activitypub 

Posted into Health Law + Business @health-law-business-BloombergLaw

0 boosts · 0 favs · 0 replies · Oct 1, 2026